News archive

02 Mar 2009US Food and Drug Administration issues complete response letter regarding the Tracleer® supplemental New Drug Application - Completion and Approval of Risk Evaluation and Mitigation System (REMS) submission required for final FDA review for inclusion of less severe PAH patients in the product label
23 Feb 2009Actelion announces acquisition of a new formulation of intravenous epoprostenol with improved thermal stability for the treatment of Pulmonary Arterial Hypertension
19 Feb 2009Actelion announces Full Year 2008 financial results
29 Jan 2009Zavesca® (miglustat) receives EU approval for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease
19 Dec 2008Miglustat (Zavesca®) receives positive opinion from the European Committee for Medicinal Products for Human Use for an extension of indication for Niemann-Pick type C disease
13 Nov 2008Actelion's first-in-class selective S1P1 receptor agonist to enter Phase II clinical development
21 Oct 2008Actelion announces 9-months results for 2008
22 Sep 2008Actelion included in the Swiss Market Index SMI
04 Aug 2008Tracleer® (bosentan) receives EU approval for treatment of patients with mildly symptomatic Pulmonary Arterial Hypertension
22 Jul 2008Actelion announces Half Year financial results 2008
14 Jul 2008Actelion and GlaxoSmithKline enter into exclusive collaboration to realise the full potential of almorexant in sleep disorders and beyond
08 Jul 2008Actelion to join the SMI (Swiss Market Index)
27 Jun 2008Bosentan (Tracleer®) receives positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension
20 Jun 2008Pivotal pulmonary arterial hypertension study published in The Lancet concludes that bosentan (Tracleer®) demonstrates benefits in patients with mildly symptomatic WHO Functional Class II disease
22 Apr 2008Actelion announces first quarter 2008 financial results
21 Apr 2008Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound
11 Apr 2008Annual General Meeting of Shareholders in Basel, Switzerland
29 Feb 2008Actelion and Nippon Shinyaku to collaborate on novel PAH compound
21 Feb 2008Actelion announces Full Year 2007 financial results
21 Jan 2008Actelion reports total net revenues for 2007
Page:  1 2 3 4 5 6 7 8 9 10 11 12 13 14

Contact

Media Relations
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Phone:+41 61 565 62 62
Fax:+41 61 565 65 07
Contact us onlineHow to get to us

Top of pageSendbookmarkPrint page